Related Experiment Video
Updated: Aug 5, 2025
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical
David A Bushinsky1, Jeffrey J Budden2, Philip A Kalra3
1University of Rochester School of Medicine and Dentistry, Rochester, New York.
Insights
Patiromer effectively reduced serum potassium and phosphorus levels in patients with chronic kidney disease and hyperkalemia within 4 weeks. This treatment was well-tolerated, showing sustained reductions in key electrolytes.
Area of Science:
- Nephrology
- Internal Medicine
- Clinical Pharmacology
Background:
- Patients with chronic kidney disease (CKD), hyperkalemia (elevated serum potassium), and hyperphosphatemia face significant clinical challenges.
- Patiromer, a medication designed to bind potassium using calcium as an exchange ion, presents a potential therapeutic option.
- Emerging evidence suggests patiromer may also impact serum phosphorus levels, warranting further investigation.
Purpose of the Study:
- To evaluate the effect of patiromer on serum phosphorus (sP) levels in patients diagnosed with CKD, hyperkalemia, and hyperphosphatemia.
- To characterize changes in serum potassium (sK+), serum calcium (sCa2+), and serum magnesium (sMg2+) concurrently with sP levels during patiromer treatment.
- To assess the tolerability and safety profile of patiromer in this patient population.
Main Methods:
- A post hoc pooled analysis was conducted using individual patient data from three pivotal clinical trials: AMETHYST-DN, OPAL-HK, and TOURMALINE.
- The analysis included 578 patients with CKD and hyperkalemia, focusing on those treated with varying daily doses of patiromer (8.4-33.6 g/day).
- Descriptive statistics were employed to summarize mean changes from baseline in sP, sK+, sCa2+, and sMg2+ at 2 and 4 weeks of treatment.
Main Results:
- Among 86 patients with baseline hyperphosphatemia, patiromer treatment led to a mean reduction in sP of -0.62±1.09 mg/dL and in sK+ of -0.71±0.51 mEq/L after 4 weeks.
- Serum magnesium levels decreased by -0.25±0.23 mg/dL, while serum calcium levels remained stable, with both electrolytes staying within normal ranges.
- Patiromer demonstrated a favorable safety profile, with no serious adverse events attributed to the medication.
Conclusions:
- Patiromer treatment resulted in significant reductions in both serum phosphorus and potassium levels in patients with CKD, hyperkalemia, and hyperphosphatemia.
- These beneficial effects on electrolyte balance were observed within 2 weeks and sustained over the 4-week treatment period.
- Further controlled trials are recommended to definitively establish patiromer's efficacy in managing both hyperkalemia and hyperphosphatemia in CKD patients.
Rationale & Objective:
Patients with chronic kidney disease (CKD), hyperkalemia (serum potassium [sK+]>5.0 mEq/L), and hyperphosphatemia experience poor clinical outcomes. Patiromer, a potassium binder that uses calcium as the exchange ion, may also reduce serum phosphorus (sP). We characterized the effect of patiromer on sP in patients with CKD, hyperkalemia, and hyperphosphatemia.
Study Design:
A post hoc pooled analysis of individual-level data from the AMETHYST-DN, OPAL-HK, and TOURMALINE trials of patiromer.
Setting & Participants:
Patients with CKD and hyperkalemia.
Exposure:
Patients treated with patiromer (8.4-33.6 g/day).
Outcome:
Mean changes from baseline in sP, sK+, serum calcium (sCa2+), and serum magnesium (sMg2+) after 2 and 4 weeks of treatment.
Analytical Approach:
Descriptive statistics to summarize pooled data on the study outcomes from the 3 studies.
Results:
We included 578 patients in the analysis. Of these participants, 86 patients (14.9%) had baseline hyperphosphatemia of whom 75.6% (65 of 86) had CKD stage 4/5 and 31.1% (153 of 492) with sP≤4.5mg/dL had CKD stage 4/5. Among the patients with elevated sP and sK+at baseline, the mean±SD reduction in sP and sK+after 4 weeks of patiromer treatment was-0.62±1.09mg/dL and-0.71± 0.51 mEq/L, respectively. Additionally, the mean±SD reduction in sMg2+in these patients was -0.25±0.23mg/dL while sCa2+remained unchanged. Both sMg2+and sCa2+remained within the normal range. Patiromer was generally well tolerated, and no serious adverse events were considered related to patiromer.
Limitations:
These were post hoc analyses, no placebo comparison was performed due to the design of the original studies, and the follow-up period was limited to 4 weeks.
Conclusions:
Reductions in sP and sK+to the normal range were observed after 2 weeks of patiromer treatment, and the reduction was sustained during 4 weeks of treatment among patients with non-dialysis-dependent CKD, hyperkalemia, and hyperphosphatemia. Future controlled trials are needed to establish if patiromer is useful to reduce both sK+and sP in hyperkalemic patients with CKD and hyperphosphatemia.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
01:20Acute Kidney Injury V: Interprofessional Care
01:29Cardiomyopathy V: Interprofessional Care
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...